- Home
- OBK vs APLT Comparison
OBK vs APLT Comparison
Compare OBK & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBK
- APLT
- Stock Information
- Founded
- OBK 1912
- APLT 2016
- Country
- OBK United States
- APLT United States
- Employees
- OBK N/A
- APLT N/A
- Industry
- OBK Major Banks
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- OBK Finance
- APLT Health Care
- Exchange
- OBK Nasdaq
- APLT Nasdaq
- Market Cap
- OBK 1.1B
- APLT 44.0M
- IPO Year
- OBK 2018
- APLT 2019
- Fundamental
- Price
- OBK $37.68
- APLT $0.42
- Analyst Decision
- OBK Buy
- APLT Buy
- Analyst Count
- OBK 5
- APLT 7
- Target Price
- OBK $42.20
- APLT $6.10
- AVG Volume (30 Days)
- OBK 148.2K
- APLT 2.6M
- Earning Date
- OBK 07-23-2025
- APLT 08-06-2025
- Dividend Yield
- OBK 1.61%
- APLT N/A
- EPS Growth
- OBK N/A
- APLT N/A
- EPS
- OBK 2.43
- APLT N/A
- Revenue
- OBK $351,348,000.00
- APLT $265,000.00
- Revenue This Year
- OBK $13.16
- APLT $1,768.13
- Revenue Next Year
- OBK $6.03
- APLT $292.85
- P/E Ratio
- OBK $15.34
- APLT N/A
- Revenue Growth
- OBK 2.92
- APLT N/A
- 52 Week Low
- OBK $28.80
- APLT $0.30
- 52 Week High
- OBK $41.17
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- OBK 61.16
- APLT 59.95
- Support Level
- OBK $36.94
- APLT $0.32
- Resistance Level
- OBK $38.05
- APLT $0.36
- Average True Range (ATR)
- OBK 0.74
- APLT 0.04
- MACD
- OBK 0.04
- APLT 0.01
- Stochastic Oscillator
- OBK 63.55
- APLT 92.91
About OBK Origin Bancorp Inc.
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.